Stop Patent Hops: Detecting “Evergreening” Patterns Through Sequential FDA Orange Book Listings
Ever wonder how a “new” drug can appear to extend market exclusivity without truly changing the underlying therapy?
In pharma, the story often isn’t about innovation—it’s about timing. And the timing is increasingly visible in the FDA’s Orange Book.
Pa…
